308 related articles for article (PubMed ID: 21646050)
1. Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.
Exley MA; Lynch L; Varghese B; Nowak M; Alatrakchi N; Balk SP
Clin Immunol; 2011 Aug; 140(2):184-95. PubMed ID: 21646050
[TBL] [Abstract][Full Text] [Related]
2. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
Front Immunol; 2018; 9():1266. PubMed ID: 29928278
[TBL] [Abstract][Full Text] [Related]
3. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
4. Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide.
Croudace JE; Curbishley SM; Mura M; Willcox CR; Illarionov PA; Besra GS; Adams DH; Lammas DA
BMC Immunol; 2008 Dec; 9():71. PubMed ID: 19055753
[TBL] [Abstract][Full Text] [Related]
5. Turned on by danger: activation of CD1d-restricted invariant natural killer T cells.
Lawson V
Immunology; 2012 Sep; 137(1):20-7. PubMed ID: 22734667
[TBL] [Abstract][Full Text] [Related]
6. Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment.
Miellot-Gafsou A; Biton J; Bourgeois E; Herbelin A; Boissier MC; Bessis N
Immunology; 2010 Jun; 130(2):296-306. PubMed ID: 20113367
[TBL] [Abstract][Full Text] [Related]
7. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
[TBL] [Abstract][Full Text] [Related]
8. Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.
Singh AK; Rhost S; Löfbom L; Cardell SL
Scand J Immunol; 2019 Sep; 90(3):e12794. PubMed ID: 31141185
[TBL] [Abstract][Full Text] [Related]
9. Invariant NKT cells facilitate cytotoxic T-cell activation via direct recognition of CD1d on T cells.
Qin Y; Oh S; Lim S; Shin JH; Yoon MS; Park SH
Exp Mol Med; 2019 Oct; 51(10):1-9. PubMed ID: 31653827
[TBL] [Abstract][Full Text] [Related]
10. Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy.
Wang Y; Sedimbi SK; Löfbom L; Besra GS; Porcelli SA; Cardell SL
Front Immunol; 2019; 10():352. PubMed ID: 30881361
[TBL] [Abstract][Full Text] [Related]
11. Amide analogues of CD1d agonists modulate iNKT-cell-mediated cytokine production.
Wojno J; Jukes JP; Ghadbane H; Shepherd D; Besra GS; Cerundolo V; Cox LR
ACS Chem Biol; 2012 May; 7(5):847-55. PubMed ID: 22324848
[TBL] [Abstract][Full Text] [Related]
12. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
13. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.
Guan P; Schaub R; Nichols KE; Das R
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464
[TBL] [Abstract][Full Text] [Related]
14. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM
Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925
[TBL] [Abstract][Full Text] [Related]
15. Distinct and overlapping effector functions of expanded human CD4+, CD8α+ and CD4-CD8α- invariant natural killer T cells.
O'Reilly V; Zeng SG; Bricard G; Atzberger A; Hogan AE; Jackson J; Feighery C; Porcelli SA; Doherty DG
PLoS One; 2011; 6(12):e28648. PubMed ID: 22174854
[TBL] [Abstract][Full Text] [Related]
16. CD1d-restricted antigen presentation by Vγ9Vδ2-T cells requires trogocytosis.
Schneiders FL; Prodöhl J; Ruben JM; O'Toole T; Scheper RJ; Bonneville M; Scotet E; Verheul HM; de Gruijl TD; van der Vliet HJ
Cancer Immunol Res; 2014 Aug; 2(8):732-40. PubMed ID: 24934445
[TBL] [Abstract][Full Text] [Related]
17. Invariant natural killer T cell-based immunotherapy for cancer.
Motohashi S; Nakayama T
Immunotherapy; 2009 Jan; 1(1):73-82. PubMed ID: 20635975
[TBL] [Abstract][Full Text] [Related]
18. Hiding lipid presentation: viral interference with CD1d-restricted invariant natural killer T (iNKT) cell activation.
Horst D; Geerdink RJ; Gram AM; Stoppelenburg AJ; Ressing ME
Viruses; 2012 Oct; 4(10):2379-99. PubMed ID: 23202469
[TBL] [Abstract][Full Text] [Related]
19. Direct CD1d-mediated stimulation of APC IL-12 production and protective immune response to virus infection in vivo.
Yue SC; Nowak M; Shaulov-Kask A; Wang R; Yue D; Balk SP; Exley MA
J Immunol; 2010 Jan; 184(1):268-76. PubMed ID: 19949077
[TBL] [Abstract][Full Text] [Related]
20. The tumor antigen N-glycolyl-GM3 is a human CD1d ligand capable of mediating B cell and natural killer T cell interaction.
Gentilini MV; Pérez ME; Fernández PM; Fainboim L; Arana E
Cancer Immunol Immunother; 2016 May; 65(5):551-62. PubMed ID: 26969612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
